EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

The relationship between 3,4‐methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid‐30s: Findings from the Victorian Adolescent Health Cohort Study

Zachary Bryant iD, Kirsten Morley iD, Jessica A Kerr iD, Craig A Olsson iD, Tim Slade iD

Addiction · 2025

DOI: 10.1111/add.70173 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Addiction, 2025. Verfasst von Zachary Bryant und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Matilda Centre for Research in Mental Health and Substance Use, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: N-Methyl-3,4-methylenedioxyamphetamine, Anxiety Disorders, Depressive Disorder, Amphetamine-Related Disorders. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Postgraduate Research Scholarship in Mental Health and Substance Use at the University of Sydney, National Health and Medical Research Council, Royal Children's Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims MDMA (3,4‐methylenedioxymethamphetamine or “Ecstasy”) is the fourth‐most used illicit substance globally. While previous research found links between MDMA use and mental health outcomes, the direction and nature of this relationship remain unclear. This study assessed whether MDMA use in early adulthood increases the risk of anxiety or depression in mid‐30s.

Design

A longitudinal, population‐based study using doubly robust inverse probability treatment weighted regression analysis, a contemporary confounder adjustment technique, to examine the relationship between MDMA use in early adulthood (age 20–29) and subsequent anxiety or depression at age 35.

Setting

Victoria, Australia.

Participants

Data were drawn from the Victorian Adolescent Health Cohort Study (VAHCS), which began in 1992 with a statewide representative sample of 1943 Year 9 students (aged 14–15) from 44 Victorian schools. This paper uses data collected from wave 2 to wave 10 (ages 15–35).

Measurements

Across waves 7–9 (ages 20–29), MDMA use was categorised as any use, persistent use (none, one wave, two or more waves) and frequent use (none, infrequent, frequent). Wave 10 (age 35) outcomes were 12‐month diagnoses of major depressive disorder and anxiety disorders assessed using the Composite International Diagnostic Interview (CIDI).

Findings

There was little evidence linking any pattern of MDMA use in early adulthood with depressive disorders by the mid‐30s; however, compared with non‐MDMA users, the adjusted odds of an anxiety disorder were higher in those who reported past 12‐month MDMA use [odds ratio (OR) = 1.73, 95% confidence interval (CI) = 1.12–2.68), persistent MDMA use at two or more waves (OR = 2.05, 95% CI = 1.07–3.94), as well as infrequent (OR = 2.11, 95% CI = 1.14–3.92) and frequent MDMA use (OR = 2.56, 95% CI = 1.15–5.71).

Conclusions

MDMA use (3,4‐methylenedioxymethamphetamine or “Ecstasy”) in early adulthood appears to be associated with increased odds of anxiety disorders but not depressive disorder by the mid‐30s.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

N-Methyl-3,4-methylenedioxyamphetamineAnxiety DisordersDepressive DisorderAmphetamine-Related DisordersHallucinogensHumansVictoriaMaleFemaleYoung AdultAdolescentAdultLongitudinal StudiesCohort Studies

Stichwörter der Autor:innen

3,4‐methylenedioxymethamphetamineMDMAanxietydepressionmental healthmoodpsychedelicsstimulantssubstance use

Substanzen

N-Methyl-3,4-methylenedioxyamphetamineHallucinogens

Autor:innen und Institutionen

  • The Matilda Centre for Research in Mental Health and Substance Use, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Discipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.
  • Murdoch Children's Research Institute, Parkville, Australia.
  • Department of Paediatrics, University of Melbourne, Parkville, Australia.
  • Deakin University, Faculty of Health, School of Psychology, SEED Centre for Lifespan Research, Burwood, Australia.

ORCID-Profile: Zachary Bryant, Kirsten Morley, Jessica A Kerr, Craig A Olsson, Tim Slade

Förderung

  • Postgraduate Research Scholarship in Mental Health and Substance Use at the University of Sydney
  • National Health and Medical Research Council
  • Royal Children's Hospital Foundation
  • Murdoch Children's Research Institute
  • Victorian Government's Operational Infrastructure Program

Zitieren

APA

Bryant, Z., Morley, K., Kerr, J. A., Olsson, C. A., & Slade, T. (2025). The relationship between 3,4‐methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid‐30s: Findings from the Victorian Adolescent Health Cohort Study. Addiction. https://doi.org/10.1111/add.70173

Vancouver

Bryant Z, Morley K, Kerr JA, Olsson CA, Slade T. The relationship between 3,4‐methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid‐30s: Findings from the Victorian Adolescent Health Cohort Study. Addiction. 2025. doi:10.1111/add.70173

BibTeX
@article{Bryant2025,
  author = {Bryant, Zachary and Morley, Kirsten and Kerr, Jessica A and Olsson, Craig A and Slade, Tim},
  title = {The relationship between 3,4‐methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid‐30s: Findings from the Victorian Adolescent Health Cohort Study},
  journal = {Addiction},
  year = {2025},
  doi = {10.1111/add.70173}
}
Kostenlos starten →